NasdaqGS - Nasdaq Real Time Price ? USD Surmodics, Inc. (SRDX) Follow Compare 37.59 -0.54 (-1.42%) At close: October 25 at 4:00 PM EDT 37.59 0.00 (0.00%) After hours: October 25 at 5:10 PM EDT All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations SRDX Stock Down Despite FDA Clearance for Pounce XL System Surmodics' latest regulatory achievement is likely to broaden the platform's clinical utility and significantly expand its addressable market. Zacks ? 23 days ago SRDX -1.42% DVA BSX Surmodics Receives FDA 510(k) Clearance for Pounce? XL Thrombectomy System, Expanding the Pounce Thrombectomy Platform to Larger Peripheral Arteries up to 10 mm in Diameter EDEN PRAIRIE, Minn., October 01, 2024--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Pounce? XL Thrombectomy System. Business Wire ? 25 days ago SRDX -1.42% SurModics (SRDX) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now SurModics (SRDX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term. Zacks ? last month SRDX -1.42% Down -5.46% in 4 Weeks, Here's Why SurModics (SRDX) Looks Ripe for a Turnaround SurModics (SRDX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock. Zacks ? last month SRDX -1.42% SurModics (SRDX) Loses -6.29% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner SurModics (SRDX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock. Zacks ? 2 months ago SRDX -1.42% Here's What Key Metrics Tell Us About SurModics (SRDX) Q3 Earnings Although the revenue and EPS for SurModics (SRDX) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. Zacks ? 2 months ago SRDX -1.42% SurModics (SRDX) Reports Q3 Loss, Tops Revenue Estimates SurModics (SRDX) delivered earnings and revenue surprises of 12.90% and 0.07%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock? Zacks ? 2 months ago SRDX -1.42% SurModics: Fiscal Q3 Earnings Snapshot EDEN PRAIRIE, Minn. AP) — SurModics Inc. SRDX) on Wednesday reported a loss of $7.6 million in its fiscal third quarter. Associated Press Finance ? 2 months ago SRDX -1.42% Surmodics Reports Third Quarter of Fiscal Year 2024 Financial Results EDEN PRAIRIE, Minn., July 31, 2024--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its third quarter ended June 30, 2024. Business Wire ? 2 months ago SRDX -1.42% Investors Will Want Surmodics' (NASDAQ:SRDX) Growth In ROCE To Persist If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an... Simply Wall St. ? 3 months ago SRDX -1.42% Surmodics (SRDX) Inks Group Purchasing Agreement With Premier Surmodics (SRDX) inks the group purchasing agreement for its thrombectomy products with Premier. Zacks ? 4 months ago SRDX -1.42% PINC BSX Surmodics Awarded Thrombectomy Products Agreement with Premier, Inc. EDEN PRAIRIE, Minn., June 10, 2024--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies, today announced it has been awarded a group purchasing agreement for thrombectomy products with Premier, Inc. Effective June 1, 2024, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for Surmodics Pounce? and Pounce? Venous Thrombectomy Systems. Business Wire ? 4 months ago SRDX -1.42% Why Is Perrigo (PRGO) Down 15.1% Since Last Earnings Report? Perrigo (PRGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. Zacks ? 4 months ago PRGO SRDX -1.42% Why Is SurModics (SRDX) Up 21.9% Since Last Earnings Report? SurModics (SRDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. Zacks ? 4 months ago SRDX -1.42% SYK Surmodics (SRDX) Enters Deal to be Acquired by GTCR for $627M Surmodics (SRDX) enters a definitive agreement to be acquired by renowned private equity company GTCR at an estimated total equity valuation of $627 million. Zacks ? 4 months ago SRDX -1.42% BSX ECL Surmodics agrees to $627M private equity buyout Surmodics will go private when the transaction closes, which is expected in the second half of the year. MedTech Dive ? 4 months ago SRDX -1.42% Surmodics Stock Rockets, But Merck Stock Little Moved, On Takeover Deals Merck and Surmodics announced big takeover deals Wednesday, but Merck stock remained at a standstill as Surmodics stock rocketed. Investor's Business Daily ? 4 months ago SRDX -1.42% Surmodics Enters into Definitive Agreement to be Acquired by GTCR for $43.00 Per Share in Cash, Representing an Approximate Equity Value of $627 Million EDEN PRAIRIE, Minn., May 29, 2024--Surmodics, Inc. (Nasdaq: SRDX), a provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it has entered into a definitive agreement to be acquired by GTCR, a leading private equity firm with a long track record of investment expertise across healthcare and healthcare technology. Business Wire ? 4 months ago SRDX -1.42% Surmodics, Inc.'s (NASDAQ:SRDX) Intrinsic Value Is Potentially 96% Above Its Share Price Key Insights The projected fair value for Surmodics is US$68.80 based on 2 Stage Free Cash Flow to Equity Surmodics is... Simply Wall St. ? 5 months ago SRDX -1.42% Here's Why You Should Hold Surmodics (SRDX) Stock for Now Surmodics' (SRDX) solid prospects in the thrombectomy business raise optimism about the stock. Zacks ? 5 months ago SRDX -1.42% DVA Performance Overview Trailing total returns as of 10/25/2024, which may include dividends or other distributions. Benchmark is S&P 500 Return SRDX S&P 500 YTD +3.41% +21.77% 1-Year +28.25% +36.74% 3-Year -31.05% +27.79%
